<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375385</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R44/ 2017</org_study_id>
    <nct_id>NCT03375385</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Propofol for Sedation in Stereotactic Brain Biopsy</brief_title>
  <official_title>Effect of Dexmedetomidine Versus Propofol on the Onset and Recovery of Sedation in Stereotactic Brain Biopsy A Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-operative anxiety leads to higher sympathetic stimulation. Propofol in the main drug used&#xD;
      during interventional or imaging techniques that need sedation. Also, dexmedetomidine causes&#xD;
      sedation, analgesia, sympatholytic properties, without respiratory depression.In stereotactic&#xD;
      brain biopsy; patient discomfort due to drilling a hole through the skull and the advancement&#xD;
      of the biopsy needle make the patient in need for good sedation and analgesia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the sedation characteristics</measure>
    <time_frame>4 hours</time_frame>
    <description>Ramsay sedation score</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>the Sedation Characteristics of Propofol and Dexmedetomidine in Patients Undergoing Stereotactic Brain Biopsy</condition>
  <arm_group>
    <arm_group_label>Hemodynamic parameters</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramsay sedation score</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraoperative side effects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>recovery of sedation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine/ propofol</intervention_name>
    <description>The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).</description>
    <arm_group_label>Hemodynamic parameters</arm_group_label>
    <arm_group_label>Intraoperative side effects</arm_group_label>
    <arm_group_label>Ramsay sedation score</arm_group_label>
    <arm_group_label>recovery of sedation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients with:&#xD;
&#xD;
          -  brain secondaries from the lung/breast/pancreas&#xD;
&#xD;
          -  tuberculoma&#xD;
&#xD;
          -  pyogenic abscess&#xD;
&#xD;
          -  intra-axial supratentorial space occupying lesion with or without hydrocephalus *an&#xD;
             average duration of the procedure 1- 2hr 30 min&#xD;
&#xD;
          -  an available caregiver for overnight observation&#xD;
&#xD;
          -  patient relative proximity to the hospital Exclusion criteria&#xD;
&#xD;
        Patients with:&#xD;
&#xD;
          -  morbid obesity (body mass index &gt;35 kg/m2)&#xD;
&#xD;
          -  significant comorbidities (a known history of hepatic disease, renal dysfunction,&#xD;
             hypertension, and chronic pain)&#xD;
&#xD;
          -  history of drug or alcohol abuse&#xD;
&#xD;
          -  an allergic reaction to one of the study medications&#xD;
&#xD;
          -  anticipated difficult airway&#xD;
&#xD;
          -  uncontrolled epilepsy&#xD;
&#xD;
          -  poor neurological status&#xD;
&#xD;
          -  neuropsychological unsuitability taking psychotropic drugs (benzodiazepines and&#xD;
             barbiturates)&#xD;
&#xD;
          -  patients with brain stem lesions (vital areas of brain)&#xD;
&#xD;
          -  un-cooperative&#xD;
&#xD;
          -  refusing adults&#xD;
&#xD;
          -  patients with ventricular drain&#xD;
&#xD;
          -  already inpatient&#xD;
&#xD;
          -  Intubated patients and those who had a prior craniotomy .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ghada M.Samir</investigator_full_name>
    <investigator_title>assistant professor of anaesthesia and intensive care</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

